Zurich Multiple Endpoint Vitamin D Trial in Knee OA Patients
Primary Purpose
Knee Osteoarthritis
Status
Completed
Phase
Phase 4
Locations
Switzerland
Study Type
Interventional
Intervention
Vitamin D3 (cholecalciferol)
Sponsored by

About this trial
This is an interventional treatment trial for Knee Osteoarthritis
Eligibility Criteria
Inclusion Criteria:
- Unilateral knee replacement due to knee osteoarthritis
- Age 60+ years
- German language skills
- community dwelling
Exclusion Criteria:
- Bi-lateral knee replacement or hip replacement planned in the trial period, or in the previous 6 months
- Chronic steroid intake
- Serum calcium corrected for serum albumin > 2.6 mmol/l
- GFR < 30 ml/min
- Severe visual or hearing impairment
- Inflammatory arthritis
- Malabsorption
- High alcohol intake
- Sarcoidosis, primary hyperparathyroidism
- History of kidney stones, lymphoma
- Chemotherapy for cancer in the previous 12 months
- Hemiplegia
- Morbus Parkinson
- Unable to walk 3 meters prior to surgery
- Bisphosphonate, parathyroid hormone , fluoride or calcitonine therapy in the last 6 months
- Zolendronate in the last year
- M. Paget (Ostitis deformans)
- Vitamin D3 intake more than 800IU/d over more than 1 month
- stay on a sunny location for more than 6 weeks per year
- heart failure
Sites / Locations
- University Hospital Zurich, Centre on Aging and Mobility
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
1: 2000 IU D3/day
2: 800 IU D3 / day
Arm Description
2000 IU vitamin D3 taken orally each day for 2 years
800 IU vitamin D3 taken orally each day for 2 years
Outcomes
Primary Outcome Measures
pain and function of the operated and non-operated knee
rate of falls
Secondary Outcome Measures
strength, balance, function, physical activity
bone density, bone quality
body composition
blood pressure
number of teeth
cost, health care utilization
facial skin keratosis (number and size)
cognitive function
depression, mental health
fasting blood glucose - insulin levels
Number of upper respiratory infections and number of any infections
bone metabolism
radiographic progression of the non-operated knee
general pain
Quality of life
Full Information
NCT ID
NCT00599807
First Posted
January 10, 2008
Last Updated
October 27, 2014
Sponsor
University of Zurich
Collaborators
Harvard School of Public Health (HSPH), Tufts University, Boston University
1. Study Identification
Unique Protocol Identification Number
NCT00599807
Brief Title
Zurich Multiple Endpoint Vitamin D Trial in Knee OA Patients
Official Title
Role of Vitamin D in Secondary Prevention of Knee Osteoarthritis: A Double-blind Randomized Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
October 2014
Overall Recruitment Status
Completed
Study Start Date
January 2008 (undefined)
Primary Completion Date
March 2014 (Actual)
Study Completion Date
March 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Zurich
Collaborators
Harvard School of Public Health (HSPH), Tufts University, Boston University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This is a 2-year double-blind randomized controlled trial in 287 community-dwelling individuals age 60 years or older undergoing uni-lateral total knee replacement due to severe OA of the knee.We compare an oral dose of 2000 IU vitamin D3 per day to 800 IU. The primary endpoints are pain and disability related to rehabilitation of the operated knee,and related to the expected high prevalence of OA in the contra-lateral knee. Secondary endpoints are change in 25(OH)D levels, muscle strength, balance, lower extremity function, the rate of falls, bone density and bone quality, bone metabolism, general pain, fall-related fractures, body composition, blood-pressure, major cardiovascular events, blood glucose-insulin levels, executive cognitive function, rate of upper respiratory tract infections / all infections, tooth loss, dental health, health care utilization, number and size of facial skin keratosis, and radiographic progression of the non-operated knee. Pain and disability will be assessed by the pain and function subscales of the Western Ontario- McMaster Universities Osteoarthritis Index (WOMAC). Randomization will be stratified by WOMAC function prior to surgery, radiological evidence for OA in the contra-lateral knee, and hospital. Clinical visits will take place at baseline (6-8 weeks after TKR), at 6, 12, 18 and 24 months of treatment. In addition, all individuals will receive a phone call every 2 month to assess adverse outcomes and compliance to treatment, supported by a hotline for immediate report of adverse events.
Statistical power: We expect more than 80% power with 200 participants completing their 24 month follow-up, and 260 participants completing their 12 month follow-up.
This is a trial with medicinal product.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Knee Osteoarthritis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
273 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1: 2000 IU D3/day
Arm Type
Active Comparator
Arm Description
2000 IU vitamin D3 taken orally each day for 2 years
Arm Title
2: 800 IU D3 / day
Arm Type
Active Comparator
Arm Description
800 IU vitamin D3 taken orally each day for 2 years
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin D3 (cholecalciferol)
Intervention Description
the intervention is a dietary supplement comparing the current standard (800 IU) to the current safe upper limit (2000 IU)
Primary Outcome Measure Information:
Title
pain and function of the operated and non-operated knee
Time Frame
0, 6,12,18, 24 months
Title
rate of falls
Time Frame
0, 24 months
Secondary Outcome Measure Information:
Title
strength, balance, function, physical activity
Time Frame
0,6,12,18,24 months
Title
bone density, bone quality
Time Frame
0, 24 months
Title
body composition
Time Frame
0, 24 months
Title
blood pressure
Time Frame
0,12,24 months
Title
number of teeth
Time Frame
0, 24 months
Title
cost, health care utilization
Time Frame
0,6,12,18,24 months
Title
facial skin keratosis (number and size)
Time Frame
0, 24 months
Title
cognitive function
Time Frame
0, 24 months
Title
depression, mental health
Time Frame
0,12,24 months
Title
fasting blood glucose - insulin levels
Time Frame
0,12,24
Title
Number of upper respiratory infections and number of any infections
Time Frame
0, 6,12,28,24
Title
bone metabolism
Time Frame
0,6,12,18,24
Title
radiographic progression of the non-operated knee
Time Frame
0, 24 months
Title
general pain
Time Frame
0,6,12,18,24 months
Title
Quality of life
Time Frame
0,6,12,18,24
10. Eligibility
Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Unilateral knee replacement due to knee osteoarthritis
Age 60+ years
German language skills
community dwelling
Exclusion Criteria:
Bi-lateral knee replacement or hip replacement planned in the trial period, or in the previous 6 months
Chronic steroid intake
Serum calcium corrected for serum albumin > 2.6 mmol/l
GFR < 30 ml/min
Severe visual or hearing impairment
Inflammatory arthritis
Malabsorption
High alcohol intake
Sarcoidosis, primary hyperparathyroidism
History of kidney stones, lymphoma
Chemotherapy for cancer in the previous 12 months
Hemiplegia
Morbus Parkinson
Unable to walk 3 meters prior to surgery
Bisphosphonate, parathyroid hormone , fluoride or calcitonine therapy in the last 6 months
Zolendronate in the last year
M. Paget (Ostitis deformans)
Vitamin D3 intake more than 800IU/d over more than 1 month
stay on a sunny location for more than 6 weeks per year
heart failure
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Heike Bischoff-Ferrari, MD, MPH
Organizational Affiliation
University Hospital Zurich, Centre on Aging and Mobility
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Zurich, Centre on Aging and Mobility
City
Zurich
State/Province
ZH
ZIP/Postal Code
8091
Country
Switzerland
12. IPD Sharing Statement
Citations:
PubMed Identifier
32542307
Citation
Abderhalden LA, Meyer S, Dawson-Hughes B, Orav EJ, Meyer U, de Godoi Rezende Costa Molino C, Theiler R, Stahelin HB, Ruschitzka F, Egli A, Forman JP, Willett WC, Bischoff-Ferrari HA. Effect of daily 2000 IU versus 800 IU vitamin D on blood pressure among adults age 60 years and older: a randomized clinical trial. Am J Clin Nutr. 2020 Sep 1;112(3):527-537. doi: 10.1093/ajcn/nqaa145.
Results Reference
derived
PubMed Identifier
31557423
Citation
Freystaetter G, Fischer K, Orav EJ, Egli A, Theiler R, Munzer T, Felson DT, Bischoff-Ferrari HA. Total Serum Testosterone and Western Ontario and McMaster Universities Osteoarthritis Index Pain and Function Among Older Men and Women With Severe Knee Osteoarthritis. Arthritis Care Res (Hoboken). 2020 Nov;72(11):1511-1518. doi: 10.1002/acr.24074.
Results Reference
derived
PubMed Identifier
31152541
Citation
Schietzel S, Fischer K, Brugger P, Orav EJ, Renerts K, Gagesch M, Freystaetter G, Stahelin HB, Egli A, Bischoff-Ferrari HA. Effect of 2000 IU compared with 800 IU vitamin D on cognitive performance among adults age 60 years and older: a randomized controlled trial. Am J Clin Nutr. 2019 Jul 1;110(1):246-253. doi: 10.1093/ajcn/nqz081.
Results Reference
derived
Learn more about this trial
Zurich Multiple Endpoint Vitamin D Trial in Knee OA Patients
We'll reach out to this number within 24 hrs